This trial enrolled premenopausal women age 18 to 55 years who had regular menstrual cycles of 21- to 35-days duration and pathologic stages I to II breast cancer, in whom all gross disease—including ductal carcinoma in situ—was surgically removed either in a one-stage or two-stage procedure.